Prescribing Lisdexamfetamine

Why Lisdexamfetamine Matters

Lisdexamfetamine is the most cleverly engineered stimulant in the modern armamentarium, and for a specific kind of patient it is the single best option on the shelf. It is a prodrug of dextroamphetamine: an inert molecule of d-amphetamine chemically tethered to the amino acid L-lysine, biologically dead until the body cleaves the lysine off and releases active drug at a slow, rate-limited pace. That one design choice solves three problems at once: it produces a smooth, long, once-daily curve without the peak-and-crash of immediate-release amphetamine; it makes the drug largely indifferent to food, gut pH, and even bariatric anatomy; and it strips out most of the abuse potential, because you cannot get a rush out of a molecule that has to be metabolized before it does anything.

Two facts anchor its clinical identity. First, among amphetamines it is among the most effective treatments we have for adult ADHD: amphetamines as a class beat methylphenidate modestly on efficacy, and lisdexamfetamine sits near the top of that class. Second, it is the only FDA-approved medication for binge eating disorder, a genuinely underserved condition, with effect sizes (0.83–0.97) that most psychiatric drugs never approach and a number-needed-to-treat of about 4 for remission.

Yet it is often passed over, sometimes for good reasons (it is an amphetamine, a Schedule II controlled substance, and methylphenidate is the safer first-line agent), sometimes for bad ones (unfamiliarity, reflexive stimulant-phobia, or the assumption that a branded-feeling drug is a marketing gimmick). Since the patent expired and roughly 18 generic versions hit the market after 2023, the old objection, cost, has largely evaporated. What remains is a drug that deserves a clear-eyed place in your algorithm.

Part 1: Indications, Who Is Lisdexamfetamine For?

FDA-Approved Uses

• ADHD in children (age ≥6) and adults
• Moderate-to-severe binge eating disorder (BED) in adults: the only FDA-approved medication for BED (approved 2015 under priority review)

Note that lisdexamfetamine is not approved for, and has failed in, several tempting off-label uses (see below). It is emphatically not a weight-loss drug, and prescribing it as one repeats a dangerous historical error.

The Evidence-Based Clinical Uses

ADHD, the core indication. A network meta-analysis (Cortese et al, Lancet Psychiatry 2018) identified amphetamines as the most effective treatments for adult ADHD, and lisdexamfetamine sits among the most effective amphetamines, with one of the largest differences from placebo in the class. Importantly, though, it shows no statistically significant superiority over other long-acting amphetamines: its edge is in how it delivers the amphetamine (smooth, long, once-daily, abuse-deterrent), not in raw efficacy over Adderall XR or Mydayis.

Its niche within ADHD:

• Patients who tolerate or respond well to amphetamines and want a genuinely long-acting, once-daily agent
• Patients converting from mixed amphetamine salts who dislike the peaks and the "crash"
• Patients with GI or absorption issues (GERD, bariatric surgery) where GI-absorbed formulations behave unpredictably
• Patients where abuse or diversion risk makes the deterrent design valuable

Binge eating disorder, the signature indication. This deserves emphasis because nothing else is FDA-approved for it. Approval rested on two 12-week RCTs (n≈745 adults with moderate-to-severe BED, baseline bingeing ~5 days/week):

• Effective doses were 50 mg/day and 70 mg/day; 30 mg/day performed no better than placebo and is a non-therapeutic dose for BED.
• Binge frequency fell by ~3.9 days/week on drug vs. ~2.4 days/week on placebo.
• Effect sizes were 0.83–0.97 (large), with a number-needed-to-treat of ~4 for remission (defined as 4+ weeks with no binge episodes).
• Patients lost roughly 6% of body weight, significantly more than placebo.

Where It Does Not Work: Learn From the Failures

• Unipolar depression augmentation: Promising Phase II signals (Trivedi 2013; Madhoo 2014) collapsed in Phase III and dose-ranging trials (Richards 2016, 2017). FDA approval was not granted. Do not reach for it as an antidepressant adjunct expecting benefit.
• Bipolar depression augmentation: A single RCT (McElroy 2015) showed no difference from placebo on the primary depression measure.

These negative results matter: the transient energy and focus a stimulant provides is not the same as an antidepressant effect, and the controlled data are clear.

Predictors of a Good Response

• Genuine, functionally impairing ADHD (not attention complaints better explained by sleep deprivation, anxiety, or overload)
• Prior good response to any amphetamine (isomer/response tends to track within class)
• Adults specifically: adults respond better to amphetamines than to methylphenidate (~80% preference for amphetamines in patients who've tried both), whereas children respond better to methylphenidate
• For BED: a clear pattern of episodic loss of control over eating, distinct from simple overeating
• Comorbid sluggish cognitive tempo: lisdexamfetamine appears to improve slow cognitive speed somewhat independently of its core ADHD effect

Predictors of a Poor Response or Poor Candidacy

• Attention complaints that are really anxiety, OCD traits, sleep deprivation, or situational overload (stimulants may worsen the first two)
• Active or unstable bipolar disorder; any psychotic disorder
• Active substance use disorder
• Uncontrolled hypertension or significant structural cardiac disease
• BED conflated with simple obesity (see below)

Part 2: Before You Start, Workup and Candidacy

There are no required baseline labs for lisdexamfetamine. The workup is a history, a screen, and vitals.

Absolute Contraindications

• Known structural cardiomyopathy
• Prolonged QT or short QT syndrome
• Brugada syndrome
• Wolff-Parkinson-White syndrome
• Marfan syndrome
• Active psychotic disorder
• Recent MI or unstable angina; uncontrolled hypertension
• Concurrent MAOI use, or within 14 days of stopping one (hypertensive crisis risk)
• Known hypersensitivity to amphetamine products

Use With Caution (Relative)

• Active or recent substance use disorder (prefer a non-stimulant; if a stimulant is essential, the abuse-deterrent design here helps)
• Bipolar I disorder (mania risk: stabilize first; methylphenidate is safer)
• Prior stimulant-induced psychosis or mania
• Anxiety/OCD-spectrum presentations (may worsen; "on-off" cycling can drive rebound anxiety)
• Elderly patients (lower doses; heightened cardiovascular sensitivity)
• Tics/Tourette's (stimulants may exacerbate; though this is more driven by the L-amphetamine isomer, and lisdexamfetamine is pure d-amphetamine)

Part 3: How to Start and Dose

Formulation

Lisdexamfetamine comes as a once-daily capsule (and a chewable tablet). The capsule can be opened and the contents dissolved in water or juice for patients who can't swallow it, one of the few practical advantages of a water-soluble prodrug. There is no immediate-release or short-acting version, by design; the whole point is the slow, rate-limited activation. With ~18 generics now available, cost and access have improved dramatically, which matters during recurrent stimulant shortages.

Available Strengths

Capsules come in 10, 20, 30, 40, 50, 60, and 70 mg (chewable tablets in a similar range), which allows clean, single-capsule titration across the therapeutic range.

Starting Dose and Titration: ADHD

• Start: 30 mg once daily in the morning. (Some clinicians start lower, 10–20 mg, in stimulant-naïve, small, elderly, or anxiety-prone patients.)
• Titrate by 10–20 mg at roughly weekly intervals as tolerated, guided by response and side effects.
• Typical effective range: 30–70 mg/day; 70 mg/day is the labeled maximum.
• Titrate to function, not to a number. Use concrete markers (homework time, work output, a spouse's report, a repeat rating scale) rather than a fixed milligram target. A 50% improvement on a rating scale is a good response.

Starting Dose and Titration: Binge Eating Disorder

• Start: 30 mg once daily, then titrate to a target of 50–70 mg/day, which is where efficacy lives.
• 30 mg/day is sub-therapeutic for BED: it did not separate from placebo. Don't stall there and conclude the drug "didn't work."

Converting From Mixed Amphetamine Salts (Adderall)

• Multiply the total daily Adderall dose by ~2.6 to approximate the lisdexamfetamine dose. This factor reflects both the shift to pure d-amphetamine and the weight of the lysine molecule.
  • Adderall 20 mg → lisdexamfetamine ~50 mg
  • Adderall 30 mg → lisdexamfetamine ~70 mg
• Treat this as a starting estimate, then adjust to the patient's actual experience. Conversion tables are approximate; absorption and isomer sensitivity vary between people.
• Trust the patient's response over the table.

Timing

• Dose in the morning, on waking. Effects begin within about 90 minutes and last up to ~14 hours, so a morning dose covers the working day and clears enough by night to protect sleep.
• Late-morning or early-afternoon dosing predictably causes insomnia; push the dose earlier if the patient reports trouble sleeping.
• Food is not a barrier: unlike Adderall XR (delayed ~2.5 hours by a fatty meal), lisdexamfetamine is delayed only ~1 hour and is otherwise indifferent to food. Patients need not time it around meals.

Part 4: Monitoring, The Schedule

Monitoring here is clinical, not laboratory. There are no routine labs or drug levels for a stable, well-responding patient.

What to Act On

• Sustained BP or HR elevation: recheck; reduce dose or reassess the agent; involve primary care/cardiology if persistent or symptomatic.
• New palpitations, syncope, or exertional chest pain: stop and get an ECG/cardiac evaluation.
• Emergent psychosis or mania: stop the stimulant and reassess the diagnosis.
• Persistent appetite suppression / weight loss (or growth deceleration in a child): manage actively (see Part 5); consider a drug holiday or dose reduction.
• Refill pattern that doesn't match the stated use pattern: address the diversion/misuse question directly.

Family or spouse input at the ~6-month mark is especially useful, since amphetamines can subtly inflate self-perception and confidence, so an outside observer helps calibrate whether the response is real.

Part 5: Side Effects and How to Manage Them

The governing principle mirrors the class: most stimulant side effects are dose-dependent, peak early, and settle over weeks; almost all are manageable by adjusting dose, timing, or formulation. Discontinuation rates in the BED trials were low (~1.5–6.3%), and patients frequently describe lisdexamfetamine as a smoother experience than immediate-release amphetamines, likely because the rate-limited RBC activation produces a plateau rather than a spike-and-crash.

Representative rates from the BED trials (drug vs. placebo) give a feel for the profile:

Appetite Suppression and Weight Loss

Common early and expected, often 8–10 lb in the first months, usually stabilizing. (In BED this is therapeutic; in ADHD it needs watching, especially in children.)

Management:

• Eat breakfast before the dose and a solid dinner after it wears off.
• Reassure that it usually self-limits; if persistent, reduce the dose or consider a drug holiday.
• In children, track height and weight on a growth chart; a scheduled holiday (weekends/summers) can allow catch-up growth if needed.

Insomnia

Very common when the drug is active into the evening.

Management:

• Dose earlier in the day: this is the single most effective fix.
• Because there's no shorter-acting version, if a morning dose still disrupts sleep, lower the dose or reconsider a shorter-acting stimulant for that patient.
• Address sleep hygiene; don't let the stimulant become a substitute for adequate sleep.

Dry Mouth (Xerostomia)

Among the most common complaints (36% in trials).

Management:

• Oral rinses/moisturizers (Biotene, SalivaMAX), sugar-free gum, hydration.
• If it progresses to gingival recession, pilocarpine (FDA-approved for xerostomia) is an option.

Cardiovascular

Expect a mild rise in BP (~1–8 mm Hg systolic) and heart rate. Clinically significant events are rare in structurally normal hearts.

Management:

• Track vitals at visits; reduce dose or reassess if sustained elevation.
• New cardiac symptoms → stop and evaluate.
• Because lisdexamfetamine is pure d-amphetamine, it carries less of the cardiac and jitteriness burden attributed to the L-amphetamine isomer (which is present in mixed salts like Adderall and, more so, in Evekeo). This is a genuine advantage for cardiac-cautious patients who still need an amphetamine.

"Crash" / Rebound

The end-of-day rebound (fatigue, irritability, dysphoria, return of symptoms) that plagues immediate-release stimulants is less prominent with lisdexamfetamine, precisely because the level tapers gradually rather than dropping off a cliff. When it does occur:

Management:

• Its long, smooth curve is already the first-line fix; there isn't a smoother oral amphetamine to switch to.
• Anecdotally, tyrosine 500 mg taken 1–2 hours before the expected wear-off may blunt rebound (as a dopamine precursor); evidence is informal.

Mood, Irritability, and Psychiatric Effects

• Irritability is often less than feared; many patients are calmer on stimulant. If it emerges, reduce the dose or consider switching to methylphenidate.
• Mania/psychosis: amphetamines carry roughly double the psychosis risk of methylphenidate. The risk is concentrated in patients with psychotic or bipolar vulnerability, which is why the up-front screen matters. New psychosis or mania means stop and reassess.
• Anxiety: stimulants can worsen anxiety and OCD-spectrum symptoms; watch for it, especially in patients whose "attention problem" was really anxiety.

Other

• Headache, jitteriness, GI upset: usually mild and dose-related.
• Tics: stimulants may exacerbate pre-existing tics; the risk is more associated with L-amphetamine, so pure-d lisdexamfetamine is a relatively favorable choice here, but monitor.
• Cognitive over-narrowing at high doses: stimulants follow an inverted-U curve: low-to-moderate doses sharpen attention, but excessive doses cause hyperfocus, rigidity, and reduced cognitive flexibility. If a patient becomes "locked in," perseverative, or robotic, the dose is too high.

Part 6: Overdose, Toxicity, and Boxed Warning

Boxed Warning

Acute Overdose

Amphetamine toxicity is a sympathomimetic and CNS-stimulant crisis:

• Cardiovascular: tachycardia, hypertension, arrhythmias, palpitations, chest pain.
• CNS: agitation, anxiety, tremor, hyperreflexia, hyperthermia, and (at severe levels) seizures.
• Psychiatric: psychosis, mania, aggression, confusion.

Overdose is an emergency-department evaluation. Management is supportive: cooling for hyperthermia, benzodiazepines for agitation and seizures, and blood-pressure/rhythm control. There is no specific antidote. Notably, the prodrug design blunts the speed of a toxic rise for a given ingestion compared with immediate-release amphetamine, but a large overdose is still dangerous.

The High-Dose Danger Zone

Data (largely from the broader amphetamine literature and animal models) show that pushing well past labeled maxima is not a free lunch:

• Neurotoxicity to dopaminergic terminals appears at high doses in animal models, more pronounced for amphetamines than methylphenidate.
• Very high doses raise the risk of psychosis, psychiatric hospitalization, and cognitive impairment (the downslope of the inverted-U curve), along with cardiac arrhythmia.

The practical rule: stay within the labeled range (≤70 mg/day). If a patient isn't responding at ceiling, switch agents rather than exceed it: there is no evidence that supra-maximal dosing helps, and clear evidence it harms.

Sudden Cardiac Death

The 2006 FDA cardiovascular advisory generated real anxiety, but the absolute risk is minuscule: on the order of 0.2–0.5 deaths per 100,000 patient-years, against a baseline pediatric rate of ~4.6/100,000. The clinical implication is not to avoid stimulants; it is to screen out the structurally abnormal or arrhythmia-prone heart before starting.

Part 7: Drug Interactions

Lisdexamfetamine has fewer pharmacokinetic interactions than most stimulants, because its activation is enzymatic (RBC-mediated) rather than dependent on gut absorption. But several interactions still matter.

Dangerous: Do Not Combine

• MAOIs (including linezolid and methylene blue): risk of hypertensive crisis and serotonin toxicity. Contraindicated within 14 days of an MAOI.

Pharmacodynamic Cautions

• Serotonergic agents (SSRIs, SNRIs, TCAs, triptans, etc.): theoretical additive risk of serotonin syndrome when combined with amphetamines, usually manageable and often co-prescribed, but be alert to it, especially at initiation or dose increases.
• Other sympathomimetics / decongestants: additive cardiovascular stimulation.
• Antipsychotics: a pharmacologic tug-of-war: the antipsychotic blocks dopamine while the stimulant releases it. The antipsychotic can blunt the stimulant's cognitive benefit, and the stimulant can worsen psychosis. There is little reason to start this combination; if a patient is already on it, confirm the rationale before changing anything.

The Food/pH Non-Interaction: A Feature

Here is where lisdexamfetamine stands apart. Immediate-release and salt-based amphetamines are exquisitely sensitive to gastric pH: acidifying foods and drinks (orange juice, coffee, soda) reduce absorption and potency, while alkalinizing agents (antacids) increase it. This is one of the largest drug-food interactions in psychopharmacology. Lisdexamfetamine is largely immune to it, because activation happens in the bloodstream, not the gut. That's why it's the preferred amphetamine after bariatric surgery and in patients with GI/pH complexity.

Metabolism

Amphetamines are CYP2D6 substrates; strong 2D6 inhibitors (bupropion, fluoxetine, paroxetine, duloxetine) can raise amphetamine exposure, clinically minor for most patients, but worth noting if side effects climb after adding one of these. Lisdexamfetamine's rate-limiting step is the RBC cleavage of lysine, which buffers some of this variability.

Useful Synergies

• Bupropion (dopaminergic) can be a rational partner or alternative for ADHD, particularly with comorbid depression or tobacco dependence.
• Alpha-2 agonists (guanfacine, clonidine) combine well for ADHD and can dampen sympathomimetic side effects.

Part 8: Special Populations

Pregnancy

Human data are limited. Amphetamines cross the placenta; signals in the literature include possible modestly increased risks of preterm birth, low birth weight, and, inconsistently, cardiac malformations, though robust causal data are lacking. The neonate may show withdrawal-like symptoms (agitation, poor feeding) after third-trimester exposure.

Practical framework: for most patients, the reasonable default is to taper off before or early in pregnancy and manage ADHD/BED with behavioral strategies, reserving continuation for cases where the functional impairment of untreated illness clearly outweighs the exposure. This is an individualized, shared decision; coordinate with obstetrics.

Lactation

Amphetamines are excreted into breast milk and reach measurable infant levels. Most authorities advise caution or avoidance; if a patient chooses to breastfeed while treated, monitor the infant for irritability, poor feeding, and poor weight gain, and coordinate with pediatrics. Data are thin, so individualize.

Elderly

• Start low, go slow. Older adults reach higher brain amphetamine levels at a given dose and are more vulnerable to cardiovascular and neurotoxic effects.
• Keep doses modest and monitor BP/HR closely; a baseline ECG is reasonable if any cardiac history.
• There is a legitimate role: low-dose stimulants can improve cognition, mood, and energy in select medically ill older adults, but cholinesterase inhibitors and some antidepressants are often better cognitive enhancers, and cardiovascular disease is a hard stop.

Renal Impairment

Clearance falls with worsening renal function.

• Severe renal impairment (eGFR 15 to <30): maximum 50 mg/day.
• End-stage renal disease (eGFR <15): maximum 30 mg/day.
• Lisdexamfetamine and its metabolites are not meaningfully dialyzable.

Hepatic Impairment

No specific dose adjustment is well established; use general caution and titrate conservatively.

Children and Adolescents

• Approved from age 6. But remember the class rule: children respond better to methylphenidate than to amphetamines, so methylphenidate is generally the first-line stimulant in kids, with lisdexamfetamine a reasonable amphetamine option when methylphenidate fails or isn't tolerated.
• Children get more appetite suppression, weight loss, insomnia, and "personality dampening" than adults. Track growth on a chart and watch for over-dulling ("zombification" signals too high a dose).
• Misuse/diversion risk rises in adolescence (ages ~14–15 onward), when teens can control their own intake and peers ask to buy or share pills. The abuse-deterrent formulation is a real asset in this age group.
• Stimulants work best inside a structured behavioral framework (parent training, school coordination), not as a standalone fix.

Part 9: Discontinuation

Stopping lisdexamfetamine is, medically, not dangerous. There is no life-threatening withdrawal syndrome as there is with alcohol, benzodiazepines, or opioids.

What actually happens on stopping:

• Return of ADHD (or binge) symptoms, often the most consequential effect functionally.
• A rebound dysphoria: days to a couple of weeks of fatigue, low motivation, and irritability, especially after long-term or higher-dose use. This is unpleasant but self-limited and not medically hazardous, and it does not create the desperate craving of a true dependence syndrome in appropriately prescribed patients.

How to stop:

• A formal taper is not medically required, but many patients appreciate a gradual reduction to soften the dysphoria, especially at higher doses (e.g., step down over a few weeks). For higher-dose patients, reducing by roughly 10–20 mg every week or two with monitoring is reasonable.
• The bigger risk of stopping is functional, not physiological: untreated ADHD impairs work, relationships, and driving safety. Plan the timing (and any bridge strategy) with that in mind: supply-chain shortages that force abrupt gaps are a real-world example where the danger is impaired function, not withdrawal.
• BED caveat: long-term maintenance data are limited, and it is not yet clear whether binge remission is sustained after discontinuation. Reassess periodically and have a relapse plan.

Legitimate reasons to stop: emergent psychosis/mania, significant cardiovascular signal, pregnancy decision, evidence of misuse/diversion, or simple loss of benefit.

Part 10: Lisdexamfetamine vs. the Alternatives

vs. Adderall XR (mixed amphetamine salts)

Same amphetamine class, comparable efficacy. Lisdexamfetamine wins on a smoother, more consistent level (RBC-rate-limited activation vs. the peaks and ~2.5-hour food delays of salts), a genuinely once-daily curve (Adderall "XR" often still needs a second dose), abuse-deterrence, and food/pH independence (bariatric, GERD). Adderall XR was historically cheaper; now that lisdexamfetamine is generic, that gap has largely closed. Honest caveat: some patients simply do better on the salts, and a meaningful minority find lisdexamfetamine "inconsistent" and prefer to switch back.

vs. Dexedrine/Zenzedi (immediate-release d-amphetamine)

Same active drug (d-amphetamine), but lisdexamfetamine delivers it slowly and smoothly instead of in short 4–6 hour pulses: better duration, less crash, far lower abuse potential.

vs. Mydayis (16-hour amphetamine)

Mydayis covers a longer day; otherwise incremental. Choose Mydayis when a patient genuinely needs >14 hours of coverage.

vs. Methylphenidate (Concerta, etc.)

This is the important comparison. Methylphenidate is the safer first-line stimulant: better tolerated, lower psychosis/mania risk, safer across comorbidities, and preferred in children. Amphetamines (including lisdexamfetamine) are modestly more effective, particularly in adults, but carry more insomnia, more appetite suppression, and more abuse/diversion risk. The reasonable algorithm: methylphenidate first (Concerta a solid default); lisdexamfetamine as a strong next step, often before or alongside other long-acting amphetamines, especially in adults, in patients wanting once-daily smoothness, or where abuse-deterrence or absorption issues tip the scales.

vs. Non-stimulants (atomoxetine, bupropion, guanfacine)

Stimulants roughly double the effect size of non-stimulants (~0.9 vs. ~0.45). Reserve non-stimulants for failed/intolerated stimulant trials, active substance-use concerns, or specific comorbidities (bupropion for depression/tobacco; alpha-2 agonists for hypertension or tics).

For BED, vs. everything else

It's the only FDA-approved drug, but CBT outperforms it (effect size ~0.8 vs. ~0.5), and SSRIs are useful when mood comorbidity dominates. So lisdexamfetamine is best positioned for BED patients who don't respond to or can't access CBT, after you've weighed abuse/diversion risk and confirmed it's genuine BED and not obesity.

Mechanism: The Short Version

Lisdexamfetamine is a prodrug: pharmacologically inert d-amphetamine covalently bound to L-lysine. After oral absorption, the lysine is enzymatically cleaved, primarily in red blood cells, not (as once assumed) in the gut, releasing active dextroamphetamine at a slow, rate-limited pace. This is the source of nearly every clinical property that distinguishes the drug:

• Smooth, plateau-like levels (a rate-limited release curve rather than a peak-and-trough), giving up-to-14-hour duration and less crash.
• Food/pH/GI independence, because activation happens in the bloodstream.
• Abuse deterrence, because snorting or injecting inert prodrug produces no rush: the molecule must be metabolized first.

The released d-amphetamine acts like any amphetamine, but more potently and selectively than the racemic mix: it blocks reuptake of dopamine and norepinephrine and (the amphetamine-specific extra action) displaces stored dopamine and norepinephrine out of vesicles and into the synapse via reverse transport. That second mechanism (which methylphenidate lacks) explains both amphetamines' slightly greater efficacy and their greater rewarding/abuse potential. As pure d-amphetamine (2–4× more potent than the L-isomer, with less of the L-isomer's cardiac load and tic liability), lisdexamfetamine delivers a cleaner isomeric profile than mixed salts.

The Bedside Cheat Sheet